Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.

Endocrine-related cancer - 11 May 2022

Moog Sophie, Salgues Betty, Braik-Djellas Yasmine, Viel Thomas, Balvay Daniel, Autret Gwennhael, Robidel Estelle, Gimenez-Roqueplo Anne-Paule, Tavitian Bertrand, Lussey-Lepoutre Charlotte, Favier Judith

Abstract excerpt

Therapies for metastatic SDHB-dependent pheochromocytoma and paraganglioma (PPGL) are limited and poorly efficient. New targeted therapies and identification of early non-invasive biomarkers of response are thus urgently needed for these patients. We characterized an in vivo allograft model of spontaneously immortalized murine chromaffin cells (imCC) with inactivation of the Sdhb gene by dynamic contrast-enhanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sunitinib
Share to Adrenal Gland Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Fluorodeoxyglucose F18

Share to Paraganglioma

Share to Pheochromocytoma

Share to Succinate Dehydrogenase

Share to Succinates

Source

Identifiers

PMID: 35348472
DOI: 10.1530/ERC-22-0030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.PMID 35348472Read ↗

A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− ratsSemantic proximity Read ↗

Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.Semantic proximity Read ↗

In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.Semantic proximity Read ↗

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitorsSemantic proximity Read ↗

Current and Future Therapeutic Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on SDHB TumorsSemantic proximity Read ↗

Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomasSemantic proximity Read ↗

Tumour microenvironment in pheochromocytoma and paragangliomaSemantic proximity Read ↗

Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report.Semantic proximity Read ↗

Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS.Semantic proximity Read ↗

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas.Semantic proximity Read ↗

Characterisation of an Adult Zebrafish Model for SDHB-Associated Phaeochromocytomas and Paragangliomas.Semantic proximity Read ↗

Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.